Fujisawa Ambisome liposomal amphotericin B will have September launch.
Executive Summary
FUJISAWA/NEXSTAR AMBISOME PHASE IV STUDIES WILL ENROLL AIDS PATIENTS with histoplasmosis and cryptococcal meningitis for treatment with the liposomal amphotericin B product. The meningitis study is ongoing and is expected to be complete in the second quarter of 1999. The company plans to begin enrolling patients in the histoplasmosis study within the next two months and to complete the study in the second quarter of 1999. Fujisawa licensed marketing and distribution rights to Ambisome from product developer Nexstar, which will co-promote the drug in the U.S.